کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6107741 1211180 2011 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Research ArticleInduction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیماری‌های گوارشی
پیش نمایش صفحه اول مقاله
Research ArticleInduction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection
چکیده انگلیسی

Background & AimsCharacterization of inflammatory mediators, such as chemokines, during acute hepatitis C virus (HCV) infection might shed some light on viral clearance mechanisms.MethodsPlasma levels of CXCR3 (CXCL9-11)- and CCR5 (CCL3-4)-associated chemokines, ALT, and HCV RNA were measured in nine injection drug users (median 26 samples/patient) before and during 10 acute (eight primary and two secondary) HCV infections. Using functional data analysis, we estimated smooth long-term trends in chemokine expression levels to obtain the magnitude and timing of overall changes. Residuals were analyzed to characterize short-term fluctuations.ResultsCXCL9-11 induction began 38-53 days and peaked 72-83 days after virus acquisition. Increases in ALT levels followed a similar pattern. Substantial negative auto-correlations of chemokine levels at 1 week lags suggested substantial week-to-week oscillations. Significant correlations were observed between CXCL10 and HCV RNA as well as ALT and CXCR3-associated chemokines measured in the preceding week, CCL3-4 expression levels did not change appreciably during acute HCV infection.ConclusionsElevation of CXCR3-associated chemokines late during acute HCV infection suggests a role for cellular immune responses in chemokine induction. Week-to-week oscillations of HCV RNA, chemokines, and ALT suggest frequent, repeated cycles of gain and loss of immune control during acute hepatitis C.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Hepatology - Volume 55, Issue 3, September 2011, Pages 545-553
نویسندگان
, , , , , , , , , , ,